c-peptide and Sepsis

c-peptide has been researched along with Sepsis* in 4 studies

Other Studies

4 other study(ies) available for c-peptide and Sepsis

ArticleYear
Evaluation of a plasma insulin model for glycaemic control in intensive care.
    Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference, 2015, Volume: 2015

    Hyperglycaemia is a common complication in the intensive care unit (ICU), and is associated with worsened outcomes. Model-based insulin therapy protocols have been shown to be safe and effective in intensive care. Such protocols rely on correct modeling of glucose-insulin dynamics. In particular, model-based control typically relies on insulin sensitivity (SI) metrics, which are heavily influenced by plasma insulin kinetics. Plasma insulin samples were taken as part of a sepsis study and compared to modeled plasma insulin. Samples were taken in septic patients at the onset of glycaemic control, and once the patient consistently met less than two of the SIRs criteria that help define sepsis. It was found that inter-patient insulin dynamics were more variable at the onset of insulin therapy, than in the later samples after sepsis abated. Overall, the model adequately captured crucial steady state dynamics. Transient dynamics in plasma insulin following a bolus were faster than modeled, indicating greater clearance of insulin than currently modeled.

    Topics: Aged; C-Peptide; Female; Half-Life; Hospital Mortality; Humans; Hyperglycemia; Insulin; Intensive Care Units; Male; Middle Aged; Models, Theoretical; Sepsis

2015
Combined zinc supplementation with proinsulin C-peptide treatment decreases the inflammatory response and mortality in murine polymicrobial sepsis.
    Shock (Augusta, Ga.), 2014, Volume: 41, Issue:4

    Zinc is a trace element vital for immune function during host response to infection. The proinsulin C-peptide has been shown to exert beneficial effects through activation of the anti-inflammatory peroxisome proliferator-activated receptor γ (PPARγ) in experimental endotoxemia. Some in vitro activities of C-peptide appear dependent on the presence of zinc. We investigated the effect of zinc supplementation before onset of sepsis on the anti-inflammatory properties of C-peptide. Male C57BL/6 mice were subjected to polymicrobial sepsis by cecal ligation and puncture (CLP). Mice received zinc gluconate (1.3 mg/kg) intraperitoneally (i.p.) for 3 days before CLP. One hour after CLP, animals received C-peptide (280 nmol/kg i.p.) or the antimicrobial agent imipenem (25 mg/kg i.p.). Cecal ligation and puncture was associated with an 11% survival rate, pulmonary leukosequestration, and liver injury. Molecular analysis in lungs of septic mice showed increased nuclear activation of the proinflammatory extracellular signal-regulated kinases 1 and 2 and nuclear factor κB, but decreased PPARγ expression, when compared with sham animals. Combination of zinc supplementation with C-peptide posttreatment significantly improved survival rate (61%) similarly to antibiotic treatment (60%), ameliorated lung architecture and liver function, reduced tissue neutrophil infiltration, and increased bacterial clearance when compared with vehicle, C-peptide, or zinc treatment alone. These beneficial effects were associated with restored lung nuclear expression of PPARγ and reduction of phosphorylated extracellular signal-regulated kinases 1 and 2 and nuclear factor κB activities in comparison to vehicle or single treatment protocols. Our data demonstrate that short-term zinc prophylaxis before the infectious insult is a requisite for the anti-inflammatory properties of C-peptide by facilitating modulation of inflammatory pathways.

    Topics: Acute Lung Injury; Animals; Bacterial Load; Bronchoalveolar Lavage Fluid; C-Peptide; Cytokines; Dietary Supplements; Drug Evaluation, Preclinical; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Liver Diseases; Male; Mice; Mice, Inbred C57BL; Neutrophil Infiltration; NF-kappa B; Sepsis; Survival Analysis; Systemic Inflammatory Response Syndrome; Zinc

2014
Retrospective study on the effect of tight glucose control in postoperative sepsis patients using an artificial pancreas.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2011, Volume: 17, Issue:6

    Tight glucose control (TGC) using a sliding scale based on intermittent blood glucose measurements occasionally can have a fatal outcome as a result of insulin-induced hypoglycemia. The present study was undertaken to examine whether the use of an artificial pancreas to achieve TGC would be possible in postoperative patients with sepsis. The retrospective study was carried out as an exploratory study, focusing on the possibility of precise evaluation of the significance of TGC as a beneficial intervention by serological monitoring of various mediators. TGC was accomplished using an artificial pancreas (STG-22; (Nikkiso, Tokyo, Japan). The patients were divided into two groups: the TGC group (6 patients with sepsis in whom the target blood glucose level set at <150 mg/dl was attempted using the artificial pancreas), and the glucose control (GC) group (6 patients with sepsis in whom glucose control was attempted using a sliding scale; target blood glucose level was set at 200 mg/dl or lower). The mean blood glucose level was 129.7 ± 9.7 mg/dl in the TGC group and 200.9 ± 14.7 mg/dl in the GC group (P < 0.01, ANOVA). No hypoglycemia associated with the artificial pancreas was seen in any of the patients. The serum levels of S100A12 and HMGB-1 tended to decrease, and those of sRAGE tended to increase, in the TGC group. Further data collection from a larger number of cases would be expected to allow a precise assessment of TGC as a potentially beneficial intervention in sepsis patients.

    Topics: Aged; Aged, 80 and over; Analysis of Variance; Blood Glucose; C-Peptide; C-Reactive Protein; Cohort Studies; Cytokines; Energy Intake; Female; Glycation End Products, Advanced; Humans; Hypoglycemia; Insulin; Male; Middle Aged; Pancreas, Artificial; Postoperative Complications; Respiration, Artificial; Retrospective Studies; Sepsis

2011
Systemic and splanchnic metabolic response to exogenous human growth hormone.
    Surgery, 1998, Volume: 123, Issue:5

    Evidence exists indicating that growth hormone (GH) resistance in some disease states such as hypercatabolic conditions may limit the metabolic benefit associated with recombinant human growth hormone (rhGH) administration. It was the purpose of this study to compare the systemic and splanchnic effects of rhGH in patients with sepsis exhibiting systemic inflammatory response syndrome (SIRS) with the response observed in normal volunteers. Because insulin-like growth factor I (IGF-I) is believed to be the dominant factor responsible for the anabolic effects of rhGH, particular attention was given to this secondary effector.. The systemic and splanchnic effects of rhGH (0.15 mg/kg/day) were studied in normal volunteers (n = 5), critically ill patients with sepsis exhibiting SIRS (n = 6), and patients with sepsis exhibiting SIRS while receiving total parenteral nutrition (n = 6). Basal and end study IGF-I, urinary urea excretion, hepatic blood flow, hepatic venous oxygen content, and splanchnic oxygen exchange were measured after a 48-hour course of rhGH.. Fasting basal IGF-I concentrations were reduced by 75% to 83% in patients with sepsis/SIRS relative to normal control subjects. After 48 hours of rhGH, peak IGF-I concentrations were 74% and 76% lower in patients in the Sepsis/SIRS and Sepsis/SIRS + Nutrition groups, respectively, compared with normal control subjects. Despite the attenuated IGF-I rise in patients, urea excretion declined by a similar magnitude in all three groups. Hepatic blood flow remained unaffected, but rhGH administration increased splanchnic oxygen consumption in all groups (control, +57%*; Sepsis/SIRS, +13%; Sepsis/SIRS + Nutr +42%*; *p < 0.05 relative to corresponding basal) resulting in a decline of basal to end therapy hepatic venous oxygen saturation (control, 67 +/- 4% to 62 +/- 11%; Sepsis/SIRS, 51% +/- 14% to 43% +/- 14%*; Sepsis/SIRS + Nutr, 62% +/- 11% to 55% +/- 16%; *p < 0.05 relative to corresponding control value), suggesting that rhGH may induce centrilobular hepatic hypoxia, which may contribute to the diminished IGF-I response.. Although critically ill patients exhibit an IGF-I increase in response to exogenous rhGH, the rise is markedly attenuated compared with healthy volunteers, indicating the presence of GH resistance. Unexpectedly, the changes in the anabolic hormone IGF-I did not appear to be related to the reduction in urea excretion. This may provide some additional evidence for IGF-I resistance. Finally, rhGH is associated with an augmented splanchnic oxygen consumption but no corresponding increase in regional blood flow. As a result, regional tissue hypoxia may arise and contribute to the impaired or suboptimal IGF-I response pattern.

    Topics: APACHE; C-Peptide; C-Reactive Protein; Critical Illness; Energy Intake; Hemodynamics; Human Growth Hormone; Humans; Insulin; Insulin-Like Growth Factor I; Liver Circulation; Middle Aged; Nitrogen; Oxygen; Parenteral Nutrition, Total; Recombinant Proteins; Reference Values; Sepsis; Splanchnic Circulation; Systemic Inflammatory Response Syndrome; Urea

1998